Pharmafile Logo
Pharmafocus logo
Advanced Search

First oral treatment for hormone-sensitive prostate cancer recommended by NICE

August 15, 2024
Research and Development Accord healthcare, Oncology, Reproductive health, hormone-sensitive, prostate cancer

Today, Accord Healthcare has announced that the National Institute for Health and Care excellence (NICE) have recommended the first oral …

News

FDA approves drug for primary biliary cholangitis

August 15, 2024
Research and Development FDA Approval, FDA approva;, Hepatology, liver, primary biliary cholangitis

Accelerated approval has been granted for Gilead Science’s Livdelzi (seladelpar) to treat primary biliary cholangitis (PBC) by the US Food …

News

Kerato Ltd Partners with University of Montreal to develop novel treatment for corneal damage

August 14, 2024
Research and Development Kerato, Opthalmology, University of Montreal, corenas

BSF the Main Market listed biotech company and owner of corneal tissue replacement company Kerato Ltd, is pleased to announce …

News
Press release

David Wheadon appointed to board of directors at Seaport Therapeutics

August 14, 2024
Corporate, Seaport Therapeutics, appointment

This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.

News

Verisense announce opening of Digital Biobank

August 14, 2024
Research and Development AI, Devices, Diagnostics, Verisense, artificial intelligence, digital health, machine learning

This week, Verisense have announced that their Digital Biobank, with data from over one million people, is open for business.

News

China CDE clears Phase 3 Study of Lisafltoclax in Newlly Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome

August 13, 2024
Clinical Research, Research and Development Ascentage Pharma, Oncology

The China Centre for Drug Evaluation (CDE) has cleared the registrational phase 3 study of lisaftoclax in combination with azacitadine …

News
Vaccine image

Pfizer releases results for severe RSV-associated LRTD treatment study

August 13, 2024
Clinical Trial Services, Research and Development Immunology, Pfizer, autoimmune, clinical trial, respiratory, vaccines

US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical trial into the safety and …

News
nasal-spray-drawing

First Nasal Spray for Treatment of Anaphylaxis approved by FDA

August 12, 2024
Research and Development Emergency Medicine, FDA, anaphylaxis, epinephrine, nasal

ARS Pharmaceuticals has been granted approval by the US Food and Drug Administration (FDA) for their epinephrine nasal spray, neffy, …

News
acute_leukemia-all

Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy

August 12, 2024
Research and Development Corporate, Curon Biopharmaceuticals, Merck, Oncology, b-cells

Merck have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire CN201, a …

News

Richmond promotes new Director of Communications and Participant Engagement

August 9, 2024
Research and Development Corporate, Richmond Pharmacology, appointment, pharmaceutical

Richmond Pharmacology is delighted to announce the promotion of Liz Romano to the new position of Director of Communications and …

Appointment

Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine

August 9, 2024
Research and Development Haematology, Janssen, New England Journal of Medicine, Obstetrics & Gynaecology, foetus, newborn, women's health

Johnson & Johnson company Janssen has announced that the results from its phase 2 trial into nipocalimab have been published …

News

Cresset collaborates with global leaders Enamine to enable the design of new Targeted Protein Degraders 

August 9, 2024
Research and Development Corporate, Cresset, Cressete, Enamine, Microbiology, Targeted Protein Degraders

This week, drug discovery company Cresset has announced the extension of its global collaboration with chemical and biological contract research …

News

Pharma services boom in China as CPHI & PMEC China posts record attendance

August 8, 2024
Conferencing, Events & Incentives, Public Relations, Sales and Marketing CPHI China, PMEC China, pharma

Domestic and international markets in Asia surging as CPHI & PMEC China welcomes a staggering 93,000 attendees 08 August, 2024, …

News
Press release
Lung xray image

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070

August 7, 2024
Research and Development Daiichi Sankyo, MSD, Merck, Oncology, antibody drug conjugate, neuroendocrine cancer, oncology, small cell lung cancer

Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced the expansion of their co-development …

News
Alzheimer's brain

Sangamo Therapeutics and Genentech team up to develop genomic medicines for neurodegenerative diseases

August 7, 2024
Research and Development Genentech, Neurology, Sangamo Therapeutics, genomic medicine, neurodegenerative diseases

Genomic medicine company Sangamo Therapeutics and Genentech have entered into a licensing agreement to develop intravenously administered genomic medicines to …

News

New Real-World Data Published in Journal of Cardiac Failure on Effectiveness

August 6, 2024
Research and Development Cardiac, Cardiology, Pfizer

Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated with tafamidis. Walton Oaks, 6th August …

News
Press release
Rheumatoid arthritis

Positive results announced for Levicept’s moderate-to-severe osteoarthritis treatment

August 6, 2024
Research and Development Levicept, Rheumatology, osteoarthritis, trial

Biotechnology company Levicept has announced positive results from its phase 2 trial into LEVI-04, for the treatment of osteoarthritis.

News
Brain picture

Clinical trials for personalised cancer vaccine used to tackle aggressive brain tumours in young adults and adolescents launched by UCLA Health

August 6, 2024
Research and Development Oncology, UCLA Health, adolescent cancer, brain tumour, cancer vaccine, clinical trial

Today, researchers at the UCLA Health Jonsson Comprehensive Cancer Center have announced that they are launching a first-of-its-kind clinical trial to …

News

National Institute for Healthcare and Excellence (NICE) recommend BRUKINSA (zanubturinib) for treatment of adult patients with marginal zone lymphoma who have received at least one prior anti-CD20-based therapy.

August 6, 2024
Research and Development BeiGene, National Institute of Healthcare and Excellence, Oncology, lymphoma, margina zone lymphoma, orphan disease

BeiGene UK announced that BRUKINSA (zanubrutinib) has been recommended by the National Institute for Health and Care Excellence (NICE) for treatment …

News
Press release

Levosert® (52mg levonorgestrel intrauterine system [IUS]) receives an 8-year licence extension in the UK for contraception

August 5, 2024
Research and Development Contraception, UK, contraception, license extension

Gedeon Richter UK Ltd. (“Richter”) today announced that the Medicines Health Regulatory Authority (MHRA) has authorised an extension to the …

News
Press release
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025